TfR-Binding Polypeptides for Brain Exposure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for transporting therapeutic agents across the blood-brain barrier (BBB) often fail to achieve prolonged exposure, particularly for targets with short half-lives like Tau and alpha-synuclein, and BACE1, which requires sustained inhibition to reduce Abeta production effectively.
Innovation Solution
The use of TfR-binding polypeptides with affinities ranging from 400 nM to 2 μM, linked to therapeutic agents, to facilitate prolonged brain exposure by modulating the mechanism of action and enhancing the therapeutic window.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If high-affinity TfR-binding polypeptides are used to transport therapeutic agents across the BBB, then transport efficiency is improved, but brain exposure duration is reduced due to rapid clearance
Solution Approach 1:
The patent applies parameter changes by systematically varying the TfR-binding affinity of polypeptides across a defined range (100 nM to 10 μM) to optimize the balance between transport efficiency and exposure duration. By selecting intermediate affinity values rather than maximum affinity, the invention achieves sustained brain exposure while maintaining adequate transport across the BBB.
Solution Approach 2:
The invention employs dynamic optimization by adjusting polypeptide affinity parameters based on specific therapeutic needs and target characteristics. The system allows for flexible selection of affinity values within the specified range to match different therapeutic scenarios, enabling adaptation between rapid clearance situations and sustained exposure requirements.
2Duration of action of moving object
If polypeptides with affinities of 400 nM to 2 μM are used, then prolonged brain exposure is achieved, but transport speed across the BBB is reduced
Solution Approach 1:
The patent defines a specific affinity parameter range (400 nM to 2 μM) that represents an optimized compromise between transport speed and exposure duration. This parameter selection ensures that polypeptides bind sufficiently to TfR for efficient transport while dissociating at appropriate rates to maintain prolonged brain exposure, resolving the speed-duration trade-off.
3Duration of action of stationary object
If sustained inhibition of BACE1 is required to reduce Abeta production, then prolonged therapeutic exposure is needed, but current methods fail to maintain exposure over time
Solution Approach 1:
The patent employs preliminary action by designing polypeptides with optimized affinity parameters that pre-establish sustained release characteristics before administration. The selected affinity range (400 nM to 2 μM) ensures that therapeutic agents are released at controlled rates over extended periods, providing reliable sustained inhibition of BACE1 and consistent reduction of Abeta production throughout the dosing interval.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in prolonged brain exposure and sustained inhibition of therapeutic targets, effectively reducing Abeta production and improving treatment outcomes for neurodegenerative diseases like Alzheimer's and Parkinson's.
Implementation Method 1
Affinity-based methods for transporting therapeutic agents across the blood brain barrier (BBB) using transferrin receptor (TfR)-binding polypeptides
Data Source
AI summary
Provided herein are methods for transporting agents across the blood brain barrier. In some embodiments, the agents bind to therapeutic targets for the treatment of neurodegenerative diseases. As described herein, the agents are linked to proteins that bind to a transferrin receptor.